tiprankstipranks
Defence Therapeutics Inc (DTCFF)
:DTCFF
US Market

Defence Therapeutics (DTCFF) Income Statement

Compare
12 Followers

Defence Therapeutics Income Statement

Last quarter (Q1 2024), Defence Therapeutics's total revenue was C$0.00, a decrease of ― from the same quarter last year. In Q1, Defence Therapeutics's net income was C$-606.86K. See Defence Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Jun 24Jun 23Jun 22Jun 21Jun 20
Total Revenue
C$ 0.00C$ 0.00C$ 0.00C$ 0.00C$ 0.00
Gross Profit
C$ -90.92KC$ -13.82KC$ 0.00C$ 0.00C$ 0.00
Operating Expenses
C$ 12.66MC$ 6.48MC$ 7.32MC$ 2.86MC$ 673.18K
Depreciation and Amortization
C$ 70.94KC$ 13.82KC$ 7.27MC$ 2.83MC$ 673.18K
EBITDA
C$ -12.68MC$ -6.48MC$ 0.00C$ -2.86MC$ -673.18K
Operating Income
C$ -12.66MC$ -6.48M--C$ -673.18K
Other Income/Expenses
C$ -537.24KC$ -387.15KC$ -70.17KC$ -33.51KC$ 0.00
Pretax Income
C$ -13.19MC$ -6.87MC$ -7.34MC$ -2.86MC$ -673.18K
Net Income
C$ -13.19MC$ -6.76MC$ -7.34MC$ -2.86MC$ -673.18K
Per Share Metrics
C$ ―C$ ―C$ ―C$ ―C$ ―
Basic EPS
C$ -0.30C$ -0.17C$ -0.20C$ -0.11C$ -0.02
Diluted EPS
C$ -0.30C$ -0.17C$ -0.20C$ -0.11C$ -0.02
Weighted Average Shares Outstanding
44.63M 39.66M 36.08M 26.60M 34.80M
Weighted Average Shares Outstanding (Diluted)
44.63M 39.66M 36.08M 26.60M 34.80M
Currency in CAD

Defence Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis